纳米驱动的双 Ferroptosis 抑制糖尿病牙周炎治疗疗法
1State Key Laboratory of Oral Diseases & National Center for Stomatology & National Clinical Research Center for Oral Diseases & Department of Prosthodontics, West China Hospital of Stomatology, Sichuan University, Chengdu, Sichuan, China.
Journal of dental research
|February 11, 2026
概括
糖尿病牙周炎与细胞死亡途径铁亡有关. 新的FGZ纳米颗粒通过向双通路,有效地抑制铁灭,促进牙周组织再生.
科学领域:
- 生物医学工程 生物医学工程
- 纳米技术 纳米技术
- 牙周病学 牙周病学
背景情况:
- 糖尿病牙周炎是一个主要的公共卫生问题,增加了全身疾病风险,并带来了治疗挑战.
- 糖尿病牙周炎的传统治疗方法在解决潜在的分子机制方面往往是无效的.
- 铁,一种依赖于铁的细胞死亡,越来越被认为是糖尿病牙周炎病理学的关键因素.
研究的目的:
- 开发一种新的纳米平台,有效地抑制糖尿病牙周炎中的铁.
- 通过双金属ZIF-8纳米平台 (FGZ NPs) 传递的离子和铁rostatin-1的协同效应的研究.
- 评估FGZNP在促进牙周组织再生方面的治疗潜力.
主要方法:
- 工程双金属ZIF-8代码交付纳米平台 (FGZ NPs) 用于持续释放离子 (Ga3+) 和铁-1 (Fer-1).
- 评估了FGZ NP对Nrf2/HO-1细胞保护通路的激活.
- 评估了FGZNP的恢复铁平衡的能力,并增强双通路铁灭抑制的抗氧化能力.
- 在糖尿病牙周炎模型中量化治疗结果,包括牙周组织再生.
主要成果:
- 通过双通道向,FGZ NPs有效地抑制了铁亡,激活了Nrf2/HO-1通道.
- 纳米平台成功地恢复了铁的平衡,并加强了抗氧化防御.
- FGZ NPs显著促进了受损的牙周组织再生.
- 这项研究强调了单通路铁灭抑制剂的局限性.
结论:
- 铁质是糖尿病牙周炎的验证治疗标.
- 开发的FGZNP为双通道铁灭抑制提供了一种新且有效的策略.
- 这项研究为生物材料的新设计范式提供了新的设计范式,以向与铁死相关的疾病.
相关概念视频
Feedback Inhibition
57.3K
Biochemical reactions are occurring constantly in cells, converting starting substances to different products, usually with the help of enzymes that speed the reactions. Without enzymes, it would take far too long for most reactions to occur to be useful to the cell!
57.3K
Pathophysiology of Diabetes
3.7K
Diabetes mellitus is a chronic metabolic disorder characterized by hyperglycemia. The four categories of diabetes are type 1 diabetes, type 2 diabetes, other specific types of diabetes, and gestational diabetes.
Type 1 diabetes is characterized by autoimmune-mediated destruction of pancreatic β cells, with environmental factors potentially triggering this process in genetically susceptible individuals. Despite many not having a family history, certain genes increase susceptibility,...
Type 1 diabetes is characterized by autoimmune-mediated destruction of pancreatic β cells, with environmental factors potentially triggering this process in genetically susceptible individuals. Despite many not having a family history, certain genes increase susceptibility,...
3.7K
Enzyme Inhibition
92.8K
Inhibitors are molecules that reduce enzyme activity by binding to the enzyme. In a normally functioning cell, enzymes are regulated by a variety of inhibitors. Drugs and other toxins can also inhibit enzymes. Some inhibitors bind to the enzyme’s active site, while others inhibit enzymatic activity by binding to other sites on the protein structure.
92.8K
Gene Therapy
27.7K
Gene therapy is a technique where a gene is inserted into a person’s cells to prevent or treat a serious disease. The added gene may be a healthy version of the gene that is mutated in the patient, or it could be a different gene that inactivates or compensates for the patient’s disease-causing gene. For example, in patients with severe combined immunodeficiency (SCID) due to a mutation in the gene for the enzyme adenosine deaminase, a functioning version of the gene can be...
27.7K
ATP Driven Pumps I: An Overview
9.9K
ATP-driven pumps, also known as transport ATPases, are integral membrane proteins. They have binding sites for ATP located on the membrane's cytosolic side and the ion-conducting domain in the transmembrane region. These pumps use the free energy released from ATP hydrolysis to move the solutes across cell membranes against an electrochemical gradient.
There are four main types of ATP-driven pumps - P-type, V-type, F-type, and ABC transporter. All these pumps are of varying complexities and...
There are four main types of ATP-driven pumps - P-type, V-type, F-type, and ABC transporter. All these pumps are of varying complexities and...
9.9K
Inhibition of Cdk Activity
6.0K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
6.0K


